NASDAQ · Biotechnology

OCS (OCS) Stock

$11.29 +2.08% NASDAQ: OCS Healthcare

Valuation

MetricValue
Price$11.29
Market Cap$645.16M
P/E Ratio-14.61
P/B Ratio7.71
P/S Ratio2506.50
EPS (TTM)$-1.81
52-Week High$34.48
52-Week Low$10.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-48.47%
ROA-40.25%
ROCE-40.31%
Gross Margin-28.89%
Operating Margin-167.41%
Net Margin-188.61%
Debt/Equity0.01
Current Ratio5.92

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$1.0M$0
Operating Profit$-13.0M$-32.0M$-81.0M$-73.0M$-79.0M
Net Profit$-19.0M$-39.0M$-89.0M$-86.0M$-95.0M
EPS$-0.57$-1.18$-2.97$-2.12$-1.81
Op Margin———-10671.1%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$37.0M$114.0M$120.0M$236.0M
Total Liabilities$119.0M$135.0M$21.0M$47.0M$40.0M
Cash$46.0M$20.0M$38.0M$28.0M$81.0M
Borrowings$114.0M$123.0M$1.0M$1.0M$2.0M

Latest News

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities GlobeNewswire · Jul 8, 2026 Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference GlobeNewswire · Jul 2, 2026 Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 GlobeNewswire · Jun 11, 2026 Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease GlobeNewswire · Jun 9, 2026 Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-25.0M$-54.0M$-47.0M$-62.0M
Investing Cash Flow$0$-7.0M$-54.0M$-18.0M$-60.0M
Financing Cash Flow$-1.0M$0$-6.0M$1.0M$0
Net Cash Flow$41.0M$-26.0M$19.0M$-11.0M$57.0M
Free Cash Flow$-14.0M$-29.0M$-54.0M$-48.0M$-63.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-4.95%
Quick Ratio5.18
Interest Coverage-79.00
Return 1Y-36.76%
Return 3Y-5.53%
Return 5Y33.99%

Ownership

Insiders Held3.51%
Institutions Held38.98%
Institutions Float Held40.40%
Institutional HolderSharesReport Date
Eqt Fund Management S.a R.l.5,900,2942026-03-31
Gildi - Lifeyrissjodur2,430,4012026-03-31
Aberdeen Group plc1,746,9462026-03-31
Pivotal bioVenture Partners Investment Advisor, LLC1,680,2832026-03-31
Wellington Management Group, LLP1,345,7282026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANAB $53.61 -1.00% -127.70 $2.31B 0.00%
BBOT $8.09 -4.82% -3.62 $648.07M 0.00%
KOD $41.58 -2.16% -8.11 $2.60B 0.00%
MNMDMind Medicine (MindMed) Inc. $20.69 +0.44% -18.83 $1.56B 0.00%
NKTR $70.68 -0.13% -6.95 $1.38B 0.00%

About OCS

OCS is led by CEO Riad Sherif, employs 49 people, headquartered in CH, publicly traded since 2021.

OCS stock trades at $11.29 with a market capitalization of $645.16M. The stock is valued at a price-to-earnings (P/E) ratio of -14.61, price-to-book of 7.71, price-to-sales of 2506.50. Over the past 52 weeks the stock has ranged between $10.52 and $34.48, and currently trades 67.3% below its 52-week high.

On profitability, OCS generates a return on equity (ROE) of -48.47%, return on capital employed of -40.31%, an operating margin of -167.41%, a net profit margin of -188.61%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides